Pfizer News

#辉瑞 2024Q1 Performance Topic #持续更新

Financial report preview

Futu NewsApr 28 15:31 · Earnings Hub

Financial Report Forecast | Revenue from COVID-19 products continues to decline. Where is Pfizer's new growth engine?

Pfizer is scheduled to announce the first quarter of 2024 results in advance of the US stock market on May 1.

Zhitong Finance15:00

Pfizer to Present Cancer Therapies at ASCO Annual Meeting, Including Advances in ADCs and Bispecific Antibodies

Pfizer Inc. (NYSE:PFE) highlights its progress in advancing new potential standards of care in Oncology at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 31 to

Benzinga9minutes ago

Options Preview | Tech giants' earnings reports continue to bombard! The Bank of America bucked the trend and sang Apple a lot before the results

Amazon and Apple are active in call options, and single Call buyers are betting higher; profits are expected to soar 257%! The share price of ultra-microcomputers may fluctuate by 14.7%.

Futu News17:52

Futu Morning Post | The “Federal Reserve Microphone” released a signal before the meeting! Even if interest rates are cut, the days of ultra-low interest rates are over

The 71-day buying trend is over! The net inflow of BlackRock's Bitcoin ETF highlights weak sentiment; Musk suddenly visited China or sought Tesla FSD's entry into China.

Futu News08:04

WHO Picks JN.1 Variant for Next Set of COVID Vaccines

Seeking AlphaApr 28 02:11

Eliminates hundreds of treatments! Pfizer (PFE.US) gene therapy approved for listing by FDA

Pfizer/PFE.us (Pfizer/PFE.us) announced that the US FDA has approved the single-use gene therapy Beqvez (fidanacogene elaparvovec) it has developed to treat adults with moderate to severe hemophilia B aged 18 or above.

Zhitong FinanceApr 27 16:08

Pfizer Options Spot-On: On April 26th, 118.91K Contracts Were Traded, With 3.21 Million Open Interest

On April 26th ET, $Pfizer(PFE.US)$ had active options trading, with a total trading volume of 118.91K options for the day, of which put options accounted for 37.64% of the total transactions, and call

Futu NewsApr 27 04:30

Sector Update: Health Care Stocks Edge Higher Late Afternoon

Health care stocks were advancing late Friday afternoon, with the NYSE Health Care Index adding 0.2% and the Health Care Select Sector SPDR Fund (XLV) up 0.1%. The iShares Biotechnology ETF (IBB) rose

MT NewswiresApr 27 03:57

More Than Half of the S&P 500 Names That Reported Results This Week Beat Top and Bottom Line - Earnings Scorecard

Seeking AlphaApr 27 03:11

FDA Green Lights Pfizer's Gene Therapy For Rare Bleeding Disorder Hemophilia

Friday, the FDA approved Pfizer Inc's (NYSE:PFE) Beqvez (fidanacogene elaparvovec-dzkt) for moderate to severe hemophilia B in adult patients who currently use factor IX (FIX) prophylaxis therapy or h

BenzingaApr 27 02:30

$3.5 million per dose! US FDA Approves Pfizer's One-Time Gene Therapy for Hemophilia B

① Beqvez is a one-off treatment that enables patients to produce coagulation factor IX and prevent bleeding; ② Pfizer's drugs have the potential to have a transformative impact on patients by reducing long-term medical and treatment burdens.

cls.cnApr 27 02:08

Pfizer Pharmaceuticals rose more than 1% to a new high of $25.53, and the US Food and Drug Administration approved its first-generation treatment for a rare hereditary hemorrhagic disease.

Pfizer Pharmaceuticals rose more than 1% to a new high of $25.53, and the US Food and Drug Administration approved its first-generation treatment for a rare hereditary hemorrhagic disease.

Zhitong FinanceApr 27 00:40

Pfizer (NYSE:PFE) Notches Up on New FDA Approval

TipRanksApr 27 00:33

Pfizer Gains as Gene Therapy Wins FDA Nod

Baystreet.caApr 26 22:03

Pfizer's Options: A Look at What the Big Money Is Thinking

Deep-pocketed investors have adopted a bullish approach towards Pfizer (NYSE:PFE), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this

BenzingaApr 26 22:02

Pfizer Receives FDA Approval for Bleeding Disorder Treatment -- Barrons.com

By Emily Dattilo Pfizer has received approval from the Food and Drug Administration for a rare genetic bleeding disorder treatment -- the drug-maker's first gene therapy to be approved in the U.S. T

Barron'sApr 26 21:35

Pfizer Hits 11-year Low

Trading EconomicsApr 26 21:30

Sector Update: Health Care Stocks Mixed Premarket Friday

Health care stocks were mixed premarket Friday as the Health Care Select Sector SPDR Fund (XLV) was down 0.3% and the iShares Biotechnology ETF (IBB) was recently up 0.2% Centene (CNC) was up 0.4% aft

MT NewswiresApr 26 21:16

Gear Up for Pfizer (PFE) Q1 Earnings: Wall Street Estimates for Key Metrics

Yahoo FinanceApr 26 21:15